Cargando…
The COVID-19 Vaccines: Recent Development, Challenges and Prospects
The highly infectious coronavirus disease 2019 (COVID-19) associated with the pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to become a global pandemic. At present, the world is relying mainly on containment and hygiene-related measures, as well as repurposed dru...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067284/ https://www.ncbi.nlm.nih.gov/pubmed/33916489 http://dx.doi.org/10.3390/vaccines9040349 |
_version_ | 1783682767251308544 |
---|---|
author | Yan, Yuxin Pang, Yoongxin Lyu, Zhuoyi Wang, Ruiqi Wu, Xinyun You, Chong Zhao, Haitao Manickam, Sivakumar Lester, Edward Wu, Tao Pang, Cheng Heng |
author_facet | Yan, Yuxin Pang, Yoongxin Lyu, Zhuoyi Wang, Ruiqi Wu, Xinyun You, Chong Zhao, Haitao Manickam, Sivakumar Lester, Edward Wu, Tao Pang, Cheng Heng |
author_sort | Yan, Yuxin |
collection | PubMed |
description | The highly infectious coronavirus disease 2019 (COVID-19) associated with the pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to become a global pandemic. At present, the world is relying mainly on containment and hygiene-related measures, as well as repurposed drugs to control the outbreak. The development of COVID-19 vaccines is crucial for the world to return to pre-pandemic normalcy, and a collective global effort has been invested into protection against SARS-CoV-2. As of March 2021, thirteen vaccines have been approved for application whilst over 90 vaccine candidates are under clinical trials. This review focuses on the development of COVID-19 vaccines and highlights the efficacy and vaccination reactions of the authorised vaccines. The mechanisms, storage, and dosage specification of vaccine candidates at the advanced stage of development are also critically reviewed together with considerations for potential challenges. Whilst the development of a vaccine is, in general, in its infancy, current progress is promising. However, the world population will have to continue to adapt to the “new normal” and practice social distancing and hygienic measures, at least until effective vaccines are available to the general public. |
format | Online Article Text |
id | pubmed-8067284 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80672842021-04-25 The COVID-19 Vaccines: Recent Development, Challenges and Prospects Yan, Yuxin Pang, Yoongxin Lyu, Zhuoyi Wang, Ruiqi Wu, Xinyun You, Chong Zhao, Haitao Manickam, Sivakumar Lester, Edward Wu, Tao Pang, Cheng Heng Vaccines (Basel) Review The highly infectious coronavirus disease 2019 (COVID-19) associated with the pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread to become a global pandemic. At present, the world is relying mainly on containment and hygiene-related measures, as well as repurposed drugs to control the outbreak. The development of COVID-19 vaccines is crucial for the world to return to pre-pandemic normalcy, and a collective global effort has been invested into protection against SARS-CoV-2. As of March 2021, thirteen vaccines have been approved for application whilst over 90 vaccine candidates are under clinical trials. This review focuses on the development of COVID-19 vaccines and highlights the efficacy and vaccination reactions of the authorised vaccines. The mechanisms, storage, and dosage specification of vaccine candidates at the advanced stage of development are also critically reviewed together with considerations for potential challenges. Whilst the development of a vaccine is, in general, in its infancy, current progress is promising. However, the world population will have to continue to adapt to the “new normal” and practice social distancing and hygienic measures, at least until effective vaccines are available to the general public. MDPI 2021-04-05 /pmc/articles/PMC8067284/ /pubmed/33916489 http://dx.doi.org/10.3390/vaccines9040349 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Yan, Yuxin Pang, Yoongxin Lyu, Zhuoyi Wang, Ruiqi Wu, Xinyun You, Chong Zhao, Haitao Manickam, Sivakumar Lester, Edward Wu, Tao Pang, Cheng Heng The COVID-19 Vaccines: Recent Development, Challenges and Prospects |
title | The COVID-19 Vaccines: Recent Development, Challenges and Prospects |
title_full | The COVID-19 Vaccines: Recent Development, Challenges and Prospects |
title_fullStr | The COVID-19 Vaccines: Recent Development, Challenges and Prospects |
title_full_unstemmed | The COVID-19 Vaccines: Recent Development, Challenges and Prospects |
title_short | The COVID-19 Vaccines: Recent Development, Challenges and Prospects |
title_sort | covid-19 vaccines: recent development, challenges and prospects |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067284/ https://www.ncbi.nlm.nih.gov/pubmed/33916489 http://dx.doi.org/10.3390/vaccines9040349 |
work_keys_str_mv | AT yanyuxin thecovid19vaccinesrecentdevelopmentchallengesandprospects AT pangyoongxin thecovid19vaccinesrecentdevelopmentchallengesandprospects AT lyuzhuoyi thecovid19vaccinesrecentdevelopmentchallengesandprospects AT wangruiqi thecovid19vaccinesrecentdevelopmentchallengesandprospects AT wuxinyun thecovid19vaccinesrecentdevelopmentchallengesandprospects AT youchong thecovid19vaccinesrecentdevelopmentchallengesandprospects AT zhaohaitao thecovid19vaccinesrecentdevelopmentchallengesandprospects AT manickamsivakumar thecovid19vaccinesrecentdevelopmentchallengesandprospects AT lesteredward thecovid19vaccinesrecentdevelopmentchallengesandprospects AT wutao thecovid19vaccinesrecentdevelopmentchallengesandprospects AT pangchengheng thecovid19vaccinesrecentdevelopmentchallengesandprospects AT yanyuxin covid19vaccinesrecentdevelopmentchallengesandprospects AT pangyoongxin covid19vaccinesrecentdevelopmentchallengesandprospects AT lyuzhuoyi covid19vaccinesrecentdevelopmentchallengesandprospects AT wangruiqi covid19vaccinesrecentdevelopmentchallengesandprospects AT wuxinyun covid19vaccinesrecentdevelopmentchallengesandprospects AT youchong covid19vaccinesrecentdevelopmentchallengesandprospects AT zhaohaitao covid19vaccinesrecentdevelopmentchallengesandprospects AT manickamsivakumar covid19vaccinesrecentdevelopmentchallengesandprospects AT lesteredward covid19vaccinesrecentdevelopmentchallengesandprospects AT wutao covid19vaccinesrecentdevelopmentchallengesandprospects AT pangchengheng covid19vaccinesrecentdevelopmentchallengesandprospects |